09.12.2012 Views

Table of Contents - WOC 2012

Table of Contents - WOC 2012

Table of Contents - WOC 2012

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>WOC</strong><strong>2012</strong> Abstract Book<br />

Free Paper: External Eye Disease, Cornea, Eye Banking<br />

Mon 20 Feb 13:30 - 15:00 Capital Suite 13<br />

FP-COR-MO 411 (1)<br />

Topical Tacrolimus 0.03% Skin Ointment in Refractory Vernal<br />

Keratoconjunctivitis (VKC).<br />

Vaidee Vikram (1) , K. Thiruvengadakrishnan (1) , Jain Amit (1)<br />

1. Aravind Eye Hospital<br />

Purpose: To study the efficacy <strong>of</strong> Topical tacrolimus 0.03% skin ointment in<br />

treating refractory vernal keratoconjunctivitis (VKC).<br />

Methods: Prospective, non randomized, case series <strong>of</strong> 5 patients with refractory<br />

VKC. Patients were treated with tacrolimus Bd for 4 weeks and Od in the next<br />

month with hydorxypropyl methylcellulose (HPMC) drops Qid for two months.<br />

Symptoms and signs were subjectively graded by the patient and the treating<br />

physician respectively at entry into the study and at all subsequent follow-up<br />

visits. Follow up was on Day 7, 14, 30, 60.<br />

Results: All patients showed complete improvement in subjective scores within<br />

2 weeks. 3 out <strong>of</strong> 5 patients showed complete resolution <strong>of</strong> papillae within<br />

6 weeks while the other two resolved by 8 weeks. All patients showed<br />

improvement in objective scores by 3 weeks. Mild stinging was the only<br />

adverse effect seen within the first few days <strong>of</strong> treatment which improved with<br />

the use <strong>of</strong> HPMC eye drops. No systemic side effects were observed<br />

Conclusions: Topical tacrolimus 0.03% ointment for severe refractory VKC<br />

appears to be an effective alternative treatment. Long term studies with a larger<br />

sample size are needed to assess the safety, efficacy and recurrence <strong>of</strong> VKC.<br />

FP-COR-MO 411 (2)<br />

The Age <strong>of</strong> Patients and Severity <strong>of</strong> Keratoconus as Predictors <strong>of</strong><br />

Clinical Outcomes After Intrastromal Corneal Ring Segments<br />

Implantation<br />

Ferrara Paulo (1) , Torquetti Leonardo (1) , Ferrara Guilherme (1) , Merayo-Lloves<br />

Jesus (2)<br />

1. Paulo Ferrara Eye Clinic<br />

2. Fernandez-Vega Eye Clinic<br />

Purpose: To evaluate the influence <strong>of</strong> age and severity <strong>of</strong> keratoconus in the<br />

clinical outcomes <strong>of</strong> implantation <strong>of</strong> Ferrara intrastromal corneal ring segments.<br />

Methods: A total <strong>of</strong> 1073 eyes <strong>of</strong> 810 patients consecutively operated from<br />

January 2006 to July 2008 were evaluated. Two independent analyses were<br />

made according to the age <strong>of</strong> patients and keratoconus staging. Four groups<br />

were created according to the age <strong>of</strong> patients: < 20 years old, 20 to 30, 30<br />

to 40 and > 40 years old. The patients were also evaluated according to<br />

the keratoconus stage (I to IV). The outcome analysis included uncorrected<br />

distance visual acuity (UDVA) and corrected distance visual acuity (CDVA).<br />

Results: The postoperative increase in UDVA and CDVA was statistically<br />

significant in all groups (p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!